-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457

Benzinga·07/16/2026 11:38:03
語音播報
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $480 to $457.